Company / R&D Expense
Arcus Biosciences, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$523.0M
FY2025
5-year range
$159.0M / $523.0M
FY2021-FY2025
Trend
+16.7%
vs FY2024
Sector context
#34 of 210
Health Care
What the data says
Arcus Biosciences, Inc.'s r&d expense of $523M is higher than 84% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $159M in FY2022 to $523M in FY2025.
Based on SEC 10-K filings.
$523M in FY2025 with a 5-year CAGR of +60.1%. Top quartile in the Health Care sector.
Improved from $340M to $523M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +48.7%
- 5-Year CAGR
- +60.1%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 210This company $523.0M Sector average $644.1M
▼
-18.8% below sector average
Key checks
Key Insights
- Arcus Biosciences, Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +60.1%, indicating consistent growth.
- In FY2025, r&d expense increased 16.7% year-over-year.
- Ranks #34 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $523.0M | +16.7% |
| FY2024 | $448.0M | +31.8% |
| FY2023 | $340.0M | +113.8% |
| FY2022 | $159.0M | -38.1% |
| FY2021 | $257.0M | +417.7% |
| FY2020 | $49.6M | -36.7% |
| FY2019 | $78.5M | +450.9% |
| FY2018 | $14.2M | -69.8% |
| FY2017 | $47.2M | +231.4% |
| FY2016 | $14.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026